Daniel Teper

Dr. Daniel Teper is the Founder, CEO and Chairman of Immune Pharmaceuticals Inc. Dr. Teper was the Managing Director for North America at Bionest Partners, a global strategy consulting firm advising pharmaceutical and public biotechnology companies, and previously a New York-based Partner at ISO Healthcare Consulting — now part of Deloitte Monitor Group. Dr. Teper started his career at Novartis global headquarters in Basel and then in the United States, where he had growing responsibilities in sales, marketing and new product development. He held senior executive positions in Europe, first at GSK as Head of Commercial Operations for Glaxo France, and then as President and Chief Operating Officer of Laboratoires Delagrange through the acquisition by Synthelabo — now part of Sanofi. He then became President of Global Operations at Havas Healthcare Worldwide, a leading marketing and communication group, where he helped launch multiple industry blockbusters. Dr. Teper was a co-founder of Novagali (NOVA), which was acquired by Japan’s Santen. Dr. Teper holds a Doctor of Pharmacy degree, or PharmD, from Paris XI University and an MBA from INSEAD.